Corrigendum: Interferon-α2b Treatment for COVID-19

Qiong Zhou[1], Virginia Chen[2], Casey P. Shannon[2], Xiao-Shan Wei[1], Xuan Xiang[1], Xu Wang[1], Zi-Hao Wang[1], Scott J. Tebbutt[2,3], Tobias R. Kollmann[4] and Eleanor N. Fish[5*]

[1] Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, [2] Prevention of Organ Failure (PROOF) Centre of Excellence & Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada, [3] Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, [4] Systems Vaccinology, Center for Precision Health, Telethon Kids Institute, Nedlands, WA, Australia, [5] Toronto General Hospital Research Institute, University Health Network & Department of Immunology, University of Toronto, Toronto, ON, Canada

Keywords: interferon, COVID-19, viral shedding, IL-6, inflammation, ARDS

A Corrigendum on

Interferon-α2b Treatment for COVID-19

by Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, Wang Z-H, Tebbutt SJ, Kollmann TR and Fish EN (2020). Front. Immunol. 11:1061. doi: 10.3389/fimmu.2020.01061

ERROR IN FIGURE/TABLE

In the original article, there was a mistake in **Table 1** as published. For 'Days from symptom onset to treatment,' the IFN+ARB and ARB values were inadvertently switched. IFN+ARB should be 8.0 [5.0,11.0] and ARB should be 17.0 [10.0, 22.0]. The corrected **Table 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 1 | Demographics and clinical characteristics of patient cohort.

	IFN n = 7	IFN+ARB n = 46	ARB n = 24	p-value
Age, yrs	41.3 (27–68)	40.4 (25–80)	64.5 (37–73)	<0.001
Male (%)	0 (0.0%)	20 (43.5%)	11 (45.8%)	0.076
Female (%)	7 (100%)	26 (56.5%)	13 (54.2%)	
Comorbidities (%)[a]	14.3%	15.2%	54.2%	0.002
Initial symptoms				
Fever (%)	57.1%	58.7%	70.8%	0.632
Cough (%)	42.9%	50.0%	54.2%	0.888
Fatigue (%)	14.3%	23.9%	37.5%	0.422
Myalgia (%)	14.3%	13.0%	29.2%	0.228
Headache (%)	14.3%	6.52%	4.17%	0.590
Pharyngalgia (%)	0.00%	13.0%	8.33%	0.742
Chest pain (%)	14.3%	6.52%	20.8%	0.134
Expectoration (%)	14.3%	8.70%	20.8%	0.281
Nausea (%)	0.00%	0.00%	4.17%	0.403
Diarrhea (%)	14.3%	4.35%	20.8%	0.081
Days from symptom onset to hospital admission[b]	8.0 [5.5, 15.5]	6.5 [3.0, 10.0]	10.0 [4.5, 19.5]	0.087
Days from symptom onset to 1st treatment[b]	8.0 [6.5, 16.00]	8.0 [5.25, 11.0]	17.0 [10.0, 22.0]	<0.001

[a]Hypertension, diabetes, COPD, chronic bronchitis, heart disease, cancer.
[b]Median and interquartile range [Q1, Q3] are reported.